Ageing vs. Disease

The relationship between ageing and disease is one of the most debated topics in biomedical science. Traditionally, medicine has drawn a sharp line between "natural" ageing and specific pathology. In this view, ageing is an inevitable, physiological decline that happens to everyone, while disease is a deviation from normal function that happens to some. However, as our understanding of molecular biology deepens, this distinction is becoming increasingly blurred. Recent reviews frame ageing as a gradual pathophysiological process that elevates risk across many disease categories, and biological ageing measures increasingly predict disease onset across systems. [1] [2]

Who This Is Useful For

This page is useful for readers trying to understand why geroscience treats ageing as more than background decline, while clinical medicine still focuses on discrete diagnoses. It is especially relevant for readers comparing biological-age concepts with standard medical classification.

Ageing as a Risk Factor

It is undisputed that age is the primary risk factor for the world's leading killers: heart disease, cancer, neurodegenerative disorders (like Alzheimer's), and type 2 diabetes. The correlation is exponential; for many of these conditions, risk rises steeply with advancing age, and large prospective cohorts emphasize age as the dominant determinant of degenerative disease risk. [1] [3]

This has led to the "Geroscience Hypothesis": the idea that the underlying molecular mechanisms of ageing (like inflammation and DNA damage) are the root causes of these diverse diseases. From this perspective, these diseases are late-stage manifestations of the ageing process itself. Treating them one by one is like playing "whack-a-mole"—curing one often leaves the patient vulnerable to another because the underlying biological terrain (the aged body) remains damaged. Studies linking accelerated biological age to higher incidence of specific diseases (such as rheumatoid arthritis and osteoarthritis) provide concrete examples of this shared-mechanism model. [2] [4] [5]

How the Distinction Usually Works

Multimorbidity

A key feature of ageing populations is multimorbidity—the presence of two or more chronic conditions in the same individual. It is rare for an elderly individual to have only heart disease or only arthritis. They often cluster together. This clustering supports the view that these are not independent events but shared symptoms of systemic biological decline, consistent with reviews that map multiple diseases to common ageing mechanisms. [1] [2]

The Debate: Is Ageing Itself a Disease?

This question is not just semantic; it has regulatory and medical implications.

Arguments Against Classifying Ageing as Disease

Historically, "disease" implies a chaotic or abnormal state. Since ageing is universal (it happens to every human), natural, and inevitable, many argue it cannot be a disease. Labifying it as such could pathologize the entire human experience of growing older, leading to ageism and the medicalization of a natural life stage.

Arguments For Classifying Ageing as Disease

Proponents argue that ageing fits the definition of disease: it is a harmful physiological process that leads to suffering, functional impairment, and death. Recognizing it as a treatable condition (or at least a targetable set of mechanisms) could unlock regulatory pathways (like FDA approval) for drugs designed to target ageing processes directly, rather than just specific downstream symptoms. In parallel, some policy and coding discussions, including how age-related conditions are represented within ICD-11-related frameworks, reflect growing interest in describing ageing-linked processes more explicitly, even though ageing itself is not simply treated as a single settled disease entity. [6]

Clinical vs. Biological Definitions

Clinical management depends on confirmed measurements, diagnosis, overall risk, symptoms, and patient circumstances. Hypertension may be managed with lifestyle measures and antihypertensive medicines; type 2 diabetes is commonly treated initially with non-insulin medicines, while insulin is appropriate in selected circumstances. Frailty is a recognized clinical syndrome that can prompt comprehensive, multidisciplinary assessment and management, but neither frailty nor a biological-age score currently triggers an approved prescription specifically intended to slow ageing. Biological-age measures built from clinical biomarkers can capture risk beyond chronological age, but they are not established treatment thresholds. [4] [5] [7] [8] [9]

Age-related arterial stiffening can contribute to rising systolic blood pressure, while hypertension can itself accelerate vascular stiffening; the relationship is bidirectional, and hypertension has multiple causes. Cardiovascular risk varies continuously across blood-pressure values, but diagnostic and treatment thresholds are evidence-based decision points that also depend on repeated measurement and clinical risk, not arbitrary divisions between identical states. Biological-age measures may identify additional risk, but they do not replace validated blood-pressure criteria. [4] [7]

Evidence Quality and Interpretation

Confidence is strong that ageing biology and chronic disease are closely linked. This is supported by mechanistic research, multimorbidity patterns, and studies showing that biological-age measures can predict disease onset and life expectancy beyond chronological age alone. [1] [2] [4] [5]

Confidence is weaker when moving from that biological link to formal classification. Whether ageing should be labeled a disease is partly a philosophical and regulatory question, not only a mechanistic one. That is why broad agreement on ageing biology does not automatically produce consensus on disease terminology. [1] [6]

What This Does Not Mean

• It does not mean every older person should be considered diseased simply because ageing raises risk.
• It does not mean all late-life biological change is pathology in the same sense as a diagnosis like diabetes or cancer.
• It does not mean biological-age measures are ready to replace established clinical diagnostic criteria.
• It does not mean the regulatory debate over classifying ageing has been settled, even if the biological link to disease is strong.

Practical Interpretation Examples

• If blood pressure rises gradually with age: Cardiovascular risk is continuous, while diagnosis and treatment decisions use repeated measurements, guideline thresholds, and the person's wider clinical risk. [7]
• If someone shows accelerated biological ageing: They may be at elevated risk before they meet formal criteria for a specific disease.
• If one chronic disease is treated successfully: The person may still remain vulnerable to other conditions if the underlying ageing biology is unchanged.

Current Conclusions

• Ageing biology predicts disease: Composite biological ageing measures are linked to earlier onset of multiple age-related conditions and reduced life expectancy. [2] [4] [5]
• Shared mechanisms drive multimorbidity: Molecular hallmarks of ageing help explain why chronic diseases cluster in older adults. [1]
• Ageing is increasingly encoded in policy and classification: ICD-11 includes ageing-related modifiers, reflecting a shift toward formal recognition of ageing processes in disease coding. [6]

What Is Still Debated

• Disease vs. risk factor: Whether ageing should be labeled a disease remains a philosophical and regulatory debate, despite agreement on its harmful biological effects. [1]
• Clinical thresholds for "accelerated ageing": There is no consensus on which biological age measures should trigger intervention, or how they should be validated across populations. [4] [5]
• Intervention targets: Which ageing mechanisms are safest and most effective to target in humans remains unsettled, even as evidence accumulates that modifying ageing biology impacts multiple diseases. [1] [2]

Summary

Whether one labels ageing as a disease or a risk factor, ageing and chronic disease are closely linked and share several molecular mechanisms without being biologically identical. Understanding this connection is shifting the paradigm from reactive disease care (treating the sick) to proactive geroscience (maintaining health by targeting the biology of ageing). [1] [2]

References

1. Guo, J., Huang, H. et al. "Aging and aging-related diseases: from molecular mechanisms to interventions." Signal Transduction and Targeted Therapy (2022). https://www.nature.com/articles/s41392-022-01251-0
2. Fraser, H. C. et al. "Biological mechanisms of aging predict age-related disease onset." Communications Biology (2022). https://pmc.ncbi.nlm.nih.gov/articles/PMC9009120/
3. UK Biobank. "Prospective studies of ageing and age-related diseases." https://www.ukbiobank.ac.uk/projects/prospective-studies-of-ageing-and-age-related-diseases/
4. Chen, L. et al. "Associations between biological ageing and the risk of, and reduced life expectancy in, rheumatoid arthritis." The Lancet Healthy Longevity (2024). https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(23)00220-9/fulltext
5. He, Q. et al. "The association between accelerated biological aging and osteoarthritis." Frontiers in Public Health (2024). https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2024.1451737/full
6. WHO ICD-11 ageing-related coding discussed in: He, Q. et al. Frontiers in Public Health (2024). https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2024.1451737/full
7. National Institute for Health and Care Excellence. "Hypertension in adults: diagnosis and management" (NG136). https://www.nice.org.uk/guidance/ng136/chapter/recommendations
8. National Institute for Health and Care Excellence. "Type 2 diabetes in adults: management—initial medicines" (NG28, updated 2026). https://www.nice.org.uk/guidance/NG28/chapter/initial-medicines
9. British Geriatrics Society. "Fit for Frailty: Recognition and management of frailty in individuals in community and outpatient settings." https://www.bgs.org.uk/sites/default/files/content/resources/files/2018-05-14/fff2_short.pdf